Redwood Pharmas IntelliGel drug delivery platform demonstrates positive results in in vitro test
Redwood Pharma’s RP101 ophthalmic drug development therapy uses the IntelliGel drug delivery platform. It has now been tested in an in vitro model to confirm that it is not irritating in the eye. As such, the well-established EpiOcular Eye Irritation Test has been used. Results are good which confirm that IntelliGel works as expected. Further development of the company’s project to treat dry eye disease continues according to plan.Results from the EpiOcular tests confirm that IntelliGel can become a safe, effective and widely used drug delivery platform for the controlled release of active